Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures

@inproceedings{Ulloa2009ReviewOL,
  title={Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures},
  author={Carol M. Ulloa and Allen Towfigh and Joseph Safdieh},
  booktitle={Neuropsychiatric disease and treatment},
  year={2009}
}
Levetiracetam is a second-generation antiepileptic drug (AED) with a unique chemical structure and mechanism of action. The extended release formulation of levetiracetam (Keppra XR(); UCB Pharma) was recently approved by the Food and Drug Administration for adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. This approval is based on a double-blind, randomized, placebo-controlled, multicenter, multinational trial. Levetiracetam XR… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 71 references

Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model

  • LV Vinogradova, CM vanRijn
  • Epilepsia
  • 2008

Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. Epilepsia

  • LV Vinogradova, CM vanRijn
  • 2008

Similar Papers

Loading similar papers…